From: Systematic review of guideline-recommended medications prescribed for treatment of low back pain
AGREE II domains and items | |
---|---|
Domain 1. Scope and Purpose | |
1. The overall objective(s) of the guideline is (are) specifically described | |
2. The health question(s) covered by the guideline is (are) specifically described | |
3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described | |
Domain 2. Stakeholder Involvement | |
4. The guideline development group includes individuals from all relevant professional groups | |
5. The views and preferences of the target population (patients, public, etc.) have been sought | |
6. The target users of the guideline are clearly defined | |
Domain 3. Rigor of Development | |
7. Systematic methods were used to search for evidence | |
8. The criteria for selecting the evidence are clearly described | |
9. The strengths and limitations of the body of evidence are clearly described | |
10. The methods for formulating the recommendations are clearly described | |
11. The health benefits, side effects, and risks have been considered in formulating the recommendations | |
12. There is an explicit link between the recommendations and the supporting evidence | |
13. The guideline has been externally reviewed by experts prior to its publication | |
14. A procedure for updating the guideline is provided | |
Domain 4. Clarity of Presentation | |
15. The recommendations are specific and unambiguous | |
16. The different options for management of the condition or health issue are clearly presented | |
17. Key recommendations are easily identifiable | |
Domain 5. Applicability | |
18. The guideline describes facilitators and barriers to its application | |
19. The guideline provides advice and/or tools on how the recommendations can be put into practice | |
20. The potential resource implications of applying the recommendations have been considered | |
21. The guideline presents monitoring and/or auditing criteria | |
Domain 6. Ethical Independence | |
22. The views of the funding body have not influenced the content of the guideline | |
23. Competing interests of guideline development group members have been recorded and addressed |